Overview

Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to test how GS-5718 can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences